Peripheral T‐cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK ‐negative
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19442 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Karthik A Ganapathi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Ki-1 Antigen, Lewis X Antigen, Lymphoma, Large-Cell, Anaplastic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Peripheral T‐cell lymphomas (PTCL) are morphologically and biologically heterogeneous and a subset expresses CD30, including anaplastic large cell lymphomas (ALCL) and a minority of PTCL, not otherwise specified (PTCL, NOS). ALCL with ALK translocations (ALCL, ALK+) are readily identified by routine diagnostic methods, but differentiating ALCL without ALK translocation (ALCL, ALK−) and PTCL, NOS expressing CD30 (PTCL CD30+) can be challenging. Furthermore, rare PTCL co‐express CD30 and CD15 (PTCL CD30+CD15+); some resemble ALCL, ALK− while others resemble classic Hodgkin lymphoma. To explore the relationship between PTCL CD30+CD15+ and ALCL, ALK−, we analysed 19 cases of PTCL with CD30 expression, previously diagnosed as ALCL, ALK− (nine cases) and PTCL CD30+CD15+ (10 cases) for DUSP22/IRF4 rearrangements, coding RNA expression and selected transcriptome analysis using the NanoString nCounter gene expression analysis platform. Unsupervised clustering showed no clear segregation between ALCL, ALK− and PTCL CD30+CD15+. Three cases previously classified as PTCL CD30+CD15+ showed DUSP22/IRF4 rearrangements, favouring a diagnosis of ALCL, ALK−. Our results suggest that cases previously designated PTCL CD30+CD15+, likely fall within the spectrum of ALCL, ALK−; additionally, a subset of ALCL, ALK− with DUSP22/IRF4 rearrangement expresses CD15, consistent with previous reports and expands the immunophenotypic spectrum of this lymphoma subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
ORCID-Profile: Karthik A Ganapathi, Elaine S Jaffe, Stefania Pittaluga
Zitieren
APA
Ganapathi, K. A., Nicolae, A., Egan, C., Geng, H., Xi, L., Pack, S. D., McFadden, J. R., Raffeld, M., Jaffe, E. S., & Pittaluga, S. (2024). Peripheral T‐cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK ‐negative. British Journal of Haematology. https://doi.org/10.1111/bjh.19442
Vancouver
Ganapathi KA, Nicolae A, Egan C, Geng H, Xi L, Pack SD, et al. Peripheral T‐cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK ‐negative. British Journal of Haematology. 2024. doi:10.1111/bjh.19442
BibTeX
@article{Ganapathi2024,
author = {Ganapathi, Karthik A and Nicolae, Alina and Egan, Caoimhe and Geng, Huimin and Xi, Liqiang and Pack, Svetlana D and McFadden, Jason R and Raffeld, Mark and Jaffe, Elaine S and Pittaluga, Stefania},
title = {Peripheral T‐cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK ‐negative},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19442}
}
EUVIMED